To include your compound in the COVID-19 Resource Center, submit it here.

Biohaven begins second Phase III of rimegepant for acute migrane

In late July, Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) said it began the second of 2

Read the full 160 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE